Overview
This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.
Description
Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.
Eligibility
Inclusion Criteria:
- Age ≥18 years at the time of consent.
- Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT).
- Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR.
Exclusion Criteria:
- Any tricuspid device currently in place.
- Anatomic contraindications.
- Need for emergent or urgent surgery.
- Left ventricular ejection fraction \<25%.


